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Abstract
Background:	Anticoagulation	control	with	vitamin-	K	antagonists	(VKAs)	in	patients	
with	atrial	fibrillation	(AF)	or	venous	thromboembolism	(VTE)	can	be	measured	using	
time	in	therapeutic	range	(TTR),	where	TTR	>65%	is	considered	good	and	low	TTR	
may be associated with low adherence.
Methods:	 This	 cross-	sectional	 observational	 study	 compared	 illness	 beliefs,	 treat-
ment	beliefs,	and	treatment	satisfaction	of	patients	with	TTR	>75%	and	TTR	<50%	
using	 validated	 tools	 to	 determine	 their	 association	 with	 TTR.	 Adults	 requiring	
chronic	VKA	therapy	were	recruited	from	2	hospital	anticoagulation	clinics	in	London,	
UK.
Results:	311	patients	with	TTR	>75%	and	214	with	TTR	<50%	were	recruited.	TTR	
>75%	patients	had	been	 taking	warfarin	on	average	over	2	years	 longer	 than	TTR	
<50%	patients	(P < .001).	Statistically	significant	differences	in	beliefs	were	found	in	
all	 subscales	 other	 than	 in	 treatment	 control,	 general	 harm,	 and	 general	 overuse.	
Cluster	analysis	determined	there	were	4	distinct	clusters	of	beliefs	among	patients.	
Multivariate	binary	logistic	regression	found	VTE	patients	were	least	likely	to	have	
poor	TTR	 (OR	=	0.49;	95%	CI	0.29,	0.77).	Patients	 in	 the	 “cautious	of	 therapy	and	
fearful	of	illness”	cluster	were	most	likely	to	have	low	TTR	(OR	=	4.75;	95%	CI	2.75,	
8.77).
Conclusion:	Illness	perceptions,	medication	beliefs	and	treatment	satisfaction	were	
associated	with	INR	control.	VTE	patients	and	those	who	were	accepting	of	both	ill-
ness	and	treatment	were	most	likely	to	have	optimal	INR	control.
K E Y W O R D S
adherence,	anticoagulation,	atrial	fibrillation,	illness	belief,	medication	beliefs,	quality	of	life,	
time	in	therapeutic	range,	venous	thromboembolism,	vitamin-K	antagonists,	warfarin
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1  | INTRODUC TION
Guidelines	 recommend	 lifelong	 anticoagulation	 in	 atrial	 fibrillation	
(AF)	in	the	presence	of	stroke	risk	factors,1,2 as well as in the second-
ary	prevention	of	venous	thromboembolism	(VTE).3,4	Nonadherence	
to	 anticoagulation	 therapy	 is	 known	 to	 impact	 treatment	 out-
comes,5,6	where	adherence	is	defined	as	the	extent	to	which	a	pa-
tient	takes	their	medication	as	prescribed.7
Time	 in	 therapeutic	 range	 (TTR)	 using	 the	 Rosendaal	 method	
indicates	international	normalized	ratio	(INR)	control,	where	a	TTR	
>65%	 is	 considered	 good	 and	 indicative	 of	 treatment	 adherence	
to	 vitamin-	K	 antagonists	 (VKAs).2,8,9	 Low	TTR	has	been	 shown	 to	
be	 associated	 with	 both	 poor	 adherence	 and	 worse	 clinical	 out-
comes.10,11	Long-	term	VKA	therapy	presents	unique	challenges	re-
garding	medication	 adherence	where	 patients	may	 consider	 them	
cumbersome	due	to	regular	laboratory	monitoring	of	INR,	frequent	
dose	changes,	and	variable	dosing	regimens	while	being	restrictive	
regarding	other	drugs	and	foods.	These	factors	may	affect	TTR,12,13 
as	well	as	treatment	satisfaction	and	quality	of	life	(QoL).14	As	TTR	is	
routinely	available	to	clinicians,	it	provides	a	means	by	which	adher-
ence can be objectively assessed.
Nonadherence	is	prevalent	in	chronic	disease	where	up	to	50%	
of	 patients	 are	 reportedly	 nonadherent.15,16	 Unintentional	 nonad-
herence	 results	 from	 a	 lack	 of	 internal	 resources	 (capacity)	 or	 ex-
ternal	resources	(practical	factors)	inhibiting	adherence.	Intentional	
nonadherence	 involves	a	conscious	underlying	perceptual	or	moti-
vational	barrier	to	adherence,	such	as	patient	beliefs	about	an	illness	
or medicines.17,18	Furthermore,	behavior	 is	 influenced	by	one’s	ca-
pability	to	adhere,	opportunity	to	adhere,	and	motivation	to	adhere,	
as	described	in	the	COM-	B	model	of	adherence,	each	factor	being	
potentially	modifiable.19-21	Among	those	requiring	chronic	anticoag-
ulation,	patients	may	be	asymptomatic	and	medication	use	is	purely	
preventative.	Therefore,	drivers	to	adhere	can	be	lacking.22
While	extensive	research	has	been	conducted	to	determine	ad-
herence	 to	VKAs,22	 there	 is	a	paucity	of	 research	determining	 the	
impact	 of	 beliefs	 and	 QoL	 on	 adherence	 to	 VKAs	 and	 TTR.	 The	
Switching	Study	 is	a	program	of	work	 investigating	the	association	
between	beliefs	and	TTR	and	 longitudinal	adherence	 in	those	who	
switch	to	a	direct	oral	anticoagulant	 (DOAC).23	The	primary	aim	of	
this	study	is	to	investigate	differences	in	the	beliefs	between	those	
with	optimal	and	suboptimal	TTR.	A	secondary	objective	is	to	inves-
tigate	whether	beliefs	and	clinical	demographic	variables	are	associ-
ated with TTR.
2  | METHODS
This	 cross-	sectional	 observational	 study	 was	 conducted	 in	 the	
outpatient	 setting	 across	 the	 two	 anticoagulation	 clinics	 of	 King’s	
College	Hospital	NHS	Foundation	Trust	in	South	East	London.	The	
Denmark	Hill	 (DH)	 site	 is	 a	 tertiary	 center	 in	 a	 densely	 populated	
inner-	city	area	with	a	skew	in	the	population	towards	lower	socio-
economic	 status.	 The	 Princess	 Royal	 University	 Hospital	 (PRUH),	
situated	between	London	and	Kent,	has	an	affluent	catchment	with	
a	predominantly	elderly	Caucasian	population.24
A	random	sample	of	patients	prescribed	VKAs	for	AF	or	second-
ary	prevention	of	VTE	with	a	TTR	>75%	over	the	previous	year	were	
identified	using	the	DAWN	(4S	Information	Systems,	Ltd.,	Cumbria,	
England)	databases	at	each	site	and	sent	a	questionnaire	pack	with	
a	patient	information	leaflet	describing	the	study,	a	consent	form,	a	
prepaid	envelope	by	which	 to	 return	 the	completed	questionnaire	
pack,	and	a	complimentary	tea	bag.	Patients	with	TTR	<50%,	were	
also	identified	via	the	DAWN	database	and	invited	to	a	pharmacist-	
led	 consultation	 in	 clinic.	 For	 the	TTR	<50%	group,	 patients	were	
purposively	 sampled,	 the	questionnaire	 pack	was	 sent	 by	mail	 ac-
companied	by	a	clinic	appointment	letter.	Questionnaires	were	to	be	
completed	at	baseline	prior	to	their	appointment	where	they	were	
counselled	and	offered	 the	opportunity	 to	change	anticoagulation	
therapy	to	a	DOAC	provided	it	was	clinically	appropriate	to	do	so.	
Patients	who	were	 switched	 to	 a	DOAC	 for	 an	unlicensed	 indica-
tion	were	done	so	under	the	 instruction	and	supervision	of	a	con-
sultant	hematologist.	Patients	were	not	incentivized	to	complete	the	
questionnaire	prior	to	their	consultation	and	were	made	aware	that	
participation	 in	the	study	would	not	 impact	subsequent	treatment	
decisions. TTR was calculated by the Rosendaal method and was 
measured	 over	 the	 previous	 12	months.	 For	 those	who	 had	 been	
prescribed	VKAs	for	less	than	12	months,	the	TTR	over	that	entire	
period	was	used,	provided	they	had	been	prescribed	VKAs	for	more	
than	3	months.
Cut-	offs	of	TTR	<50%	and	TTR	>75%	were	selected	as	a	binary	
variable	was	required	for	 logistic	regression.	The	cut	off	for	“good”	
control	is	typically	set	at	65%.2,8	As	TTR	is	dynamic,	extremes	were	
opted	 for	 to	determine	clear	differences	between	 those	with	opti-
mal	control	and	those	with	poor	control.	Furthermore,	research	has	
demonstrated	that	compared	to	the	poorly	controlled	cohort	with	a	
median	TTR	of	50%,	those	with	a	TTR	>75%	were	far	less	likely	to	suf-
fer	a	major	event	(HR	=	0.164,	P < .05).25	As	such,	the	decided	cut-	offs	
were	deemed	both	clinically	appropriate	and	statistically	necessary.
Essentials
•	 Study	comparing	illness	beliefs,	treatment	beliefs	and	treatment	satisfaction	according	to	TTR.
•	 TTR	<50%	associated	with	negative	health	beliefs	compared	to	TTR	>75%.
•	 Cluster	analysis	generated	belief	profiles,	where	different	profiles	were	associated	with	TTR.
•	 Indicates	beliefs	that	can	be	targets	for	interventions	to	improve	adherence	and	TTR.
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To	be	eligible	for	the	study,	patients	needed	to	be:	aged	over	18,	
prescribed	lifelong	anticoagulation,	VKA	treatment	duration	greater	
than	12	weeks,	capable	of	providing	informed	consent,	and	able	to	
read	English.	Patients	with	active	cancer,	autoimmune	disease,	and	
metallic	heart	valves	were	excluded	from	the	study.
Clinical	and	demographic	data	was	collected	and	CHA2DS2VASc,	
CHADS2,	HAS-	BLED,	Charlson	comorbidity	index	(CCI),	and	SAMe-	
TT₂R	 scores	 calculated.26-30	 As	 the	HAS-	BLED	 scoring	 system	 for	
determining	bleeding	risk	allocates	1	point	 for	TTR	<60%	which	 is	
also	the	grouping	variable,	true	HAS-	BLED	and	adjusted	HAS-	BLED	
scores	were	 calculated,	where	 the	 adjusted	HAS-	BLED	 score	 dis-
counts	the	point	allocated	for	TTR	<60%.
2.1 | Study tools
Illness	 beliefs,	 medication	 beliefs,	 and	 treatment	 satisfaction/
anticoagulation-	specific	quality	of	life	were	assessed	using	a	question-
naire	pack	comprised	of	the	Revised	Illness	Perceptions	Questionnaire	
(IPQ-	R),	 the	 Beliefs	 about	Medicines	Questionnaire	 (BMQ),	 and	 the	
Anti-	Clot	Treatment	Scale	 (ACTS),	 respectively.31-33	Questions	 in	 the	
IPQ-	R	and	BMQ	are	answered	on	a	5-	point	Likert	scale	“strongly	disa-
gree”	ascending	to	“strongly	agree”	which	are	scored	as	1	and	5,	respec-
tively.	ACTS	is	answered	on	a	5-	point	Likert	scale	ranging	from	“not	at	
all”	to	“extremely”	scored	as	1	and	5,	respectively.
The	 IPQ-	R	 and	 BMQ	 are	 derived	 from	 Leventhal’s	 Common	
Sense	Model	of	Health	and	Illness	(CSM)	which	explains	that	when	
confronted	with	health	threats,	coping	mechanisms	deconstruct	the	
threat	 into	various	 illness	representations:	 identity,	timeline	acute-	
chronic,	timeline	cyclical,	consequences,	personal	control,	treatment	
control,	 cause,	 illness	 control,	 and	 emotional	 distress.31	 The	BMQ	
assesses	 beliefs	 regarding	 medication	 on	 four	 subscales;	 general	
harm	 and	 general	 overuse	 explore	 beliefs	 surrounding	medication	
in	general.	Specific	necessity	determines	the	extent	the	patient	rec-
ognises	the	need	for	VKA	therapy,	while	the	specific	concern	sub-
scale	 determines	 how	 strong	 their	 anxieties	 towards	 VKAs	 are.32 
The	 ACTS	 measures	 anticoagulation-	specific	 QoL	 and	 treatment	
satisfaction	 on	 two	 subscales:	 benefits	 and	 burdens	 of	 anticoag-
ulation	 therapy.33,34	 For	 descriptions	 of	 all	 subscales	 see	 Table	1.	
The	 Cronbach’s	 alpha	 test	 for	 internal	 consistency	 was	 used	 on	
each	 of	 the	 questionnaire	 subscales	where	 an	 alpha	 score	 >0.6	 is	
considered reliable.35	 All	 subscales	 had	 Cronbach’s	 α	 scores	 >0.6	
other than treatment control where α	=	0.407	and	accidental	cause	
α	=	0.170,	the	latter	being	consistent	with	the	validation	study.31	See	
Supplementary	Table	S1.
2.2 | Statistical analysis
Data	 from	completed	questionnaires	were	analyzed	using	Statistical	
Package	for	the	Social	Sciences	(SPSS)	version	24,	(IBM	Corp.,	Armonk,	
NY).	Descriptive	 statistics	were	used	 to	describe	clinical	 and	demo-
graphic	 variables.	 Chi-	squared	 tests	 were	 used	 to	 compare	 nomi-
nal	 variables.	Continuous	variables	were	assessed	 for	normality	 and	
TABLE  1 Subscale	Description	and	Scoring
Questionnaire Subscale Description Minimum score Maximum score
IPQ-	R Timeline	Acute	Chronic Patient’s	perception	of	disease	duration 6 30
Timeline	Cyclical Patient	perception	that	disease	will	come	
and	go
4 20
Consequences Patient	perception	of	disease	impact 6 30
Personal	Control Extent	to	which	patient	believes	they	can	
impact	disease	outcome,	i.e.,	self-	efficacy
6 30
Treatment	Control Extent	to	which	patient	believes	treatment	
will	be	able	to	manage	disease
6 30
Illness	Coherence Patient	self-	reported	understanding	of	
illness
5 25
Emotional	Response Emotional	response	evoked	by	illness 6 30
BMQ General Harm Extent	to	which	patient	believes	any	
medication	is	harmful
4 20
General Overuse Extent	to	which	patient	believes	medicines	
are overused in health care
4 20
Specific	Concern Patient	anticoagulation	specific	concerns 5 25
Specific	Necessity Patient’s	perceived	need	for	anticoagula-
tion	therapy
5 25
ACTS Burdens Anticoagulation-	specific	impediments	to	
quality	of	life
12 60
Benefits Patient-	reported	gains	from	anticoagula-
tion	therapy
3 15
ACTS,	Anti-	Clot	Treatment	Scale;	BMQ,	Beliefs	about	Medicines	Questionnaire;	IPQ-	R,	Revised	Illness	Perception	Questionnaire.
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independent	t	tests	were	conducted	to	compare	continuous	variables	
including	subscale	scores.	Non-	normally	distributed	subscales	would	
be	compared	using	Wilcoxon-	rank	tests.	Necessity-	concerns	differen-
tials	(NCDs)	were	calculated	by	subtracting	the	specific	concerns	sub-
scale	score	from	the	specific	necessity	subscale	score,	where	positive	
differentials	 indicate	 that	 necessity	 beliefs	 outweigh	 concerns.36	All	
tests	were	2-	tailed	with	significance	set	at	P ≤ .05.
Cluster	analysis	was	performed	on	subscale	scores	 to	profile	pa-
tients	according	to	beliefs,	other	than	causes	subscales.	Cluster	anal-
ysis	reduces	the	number	of	variables	and	groups	subjects	according	to	
the	entirety	of	their	beliefs.	Hierarchical	cluster	analysis	using	Ward’s	
method	with	 squared	Euclidean	distance	 for	pairing	of	 subjects	was	
used.	One-	way	analysis	of	variance	(ANOVA)	was	undertaken	to	de-
termine	differences	in	subscale	scores	between	clusters.	Assuming	un-
equal	homogeneity	of	variance,	the	Games-	Howell	post	hoc	test	was	
used	to	establish	differences	between	individual	clusters.	Descriptive	
characteristics	of	each	cluster’s	subscale	scores	were	calculated	by	sep-
arating	the	mean	subscale	score	for	the	cluster	into	four	equal	quartiles	
from	high	 to	 low.	To	determine	any	association	between	beliefs	and	
TTR	category,	univariate	binary	 logistic	regression	was	performed	to	
establish which variables would be entered into a multivariate binary 
logistic	regression	model.	Variables	with	P ≤ .1	at	the	univariate	stage	
were	entered	into	a	backwards	elimination	logistic	regression	multivar-
iate	analysis	modelling	for	TTR	<50%	(see	supplementary	materials	for	
variables).	Continuous	variables	were	 tested	 for	 linearity	of	 the	 logit	
prior	to	this	stage,	variables	that	did	not	pass	this	test	were	excluded	
from	the	multivariate	stage.	Bootstrapping	was	performed	in	the	inde-
pendent	t	tests	and	regression	analyses	to	eliminate	bias	from	unequal	
sample	sizes	in	each	group.
Each	subscale	had	a	mean	score	calculated	to	account	for	any	miss-
ing	answers.	Subscales	with	six	items	were	allowed	a	maximum	of	two	
missing	answers	while	subscales	with	less	than	six	items	were	allowed	a	
maximum	of	one	missing	answer	to	be	included	in	the	final	analysis.	The	
ACTS	burdens	subscale	required	a	minimum	of	9	out	of	12	answered	
questions	to	be	included	in	analysis.	TTR	<50%	patients	who	returned	
incomplete	questionnaires	were	asked	to	complete	the	missed	answers	
following	the	consultation	and	providing	consent.	TTR	>75%	patients	
were	not	approached	to	complete	incomplete	questionnaires.
2.3 | Power calculation
Assuming	a	recruitment	ratio	of	1:1	of	TTR	>75%:	TTR	<50%,	a	total	
sample	size	of	180	to	240	patients	would	be	able	to	accommodate	
12	predictive	variables	for	binary	logistic	regression;	i.e.,	up	to	120	
patients	with	TTR	>75%	and	up	to	120	patients	with	TTR	<50%.	As	
TTR	 <50%	patients	would	 enter	 a	 longitudinal	 study	which	 had	 a	
recruitment	target	of	240,	a	recruitment	ratio	of	1:1	was	maintained	
for	this	study.
2.4 | Ethical approval
This	 study	 was	 reviewed	 and	 approved	 by	 the	 London-	Dulwich	
Research	 Ethics	 Committee	 (13/LO/1468)	 and	 King’s	 College	
Hospital	 NHS	 Foundation	 Trust	 research	 and	 development	
(KCH14-	111).
3  | RESULTS
Between	September	2014	and	October	2016,	525	patients	were	
recruited.	Of	1049	questionnaires	mailed	 to	TTR	>75%	patients,	
326	 (31%)	were	 returned	 and	 15	 of	 these	were	 incomplete	 and	
not	 used.	 The	 identity	 section	of	 IPQ-	R	was	 consistently	 poorly	
answered	 with	 many	 patients	 leaving	 several	 questions	 blank,	
therefore	this	section	of	the	IPQ-	R	was	not	analyzed.	Patients	in	
TTR	>75%	were	older	 and	had	been	prescribed	VKAs	 for	 longer	
than	those	with	TTR	<50%	across	all	disease	groups	(P < .001	for	
all),	see	Table	2.	Among	AF	patients	there	were	no	differences	in	
stroke	risk	as	calculated	by	either	CHADS2	or	CHA2DS2VASc	be-
tween	groups,	nor	was	there	any	difference	in	adjusted	HAS-	BLED	
score	between	groups.
3.1 | Differences in beliefs
Amongst	AF	 patients,	 those	with	 TTR	 >75%	had	 stronger	 chronic	
timeline	beliefs	and	were	less	likely	to	believe	that	their	illness	was	
cyclical	(Table	3).	TTR	<50%	patients	had	greater	concern	about	the	
consequence	of	 their	 illness	while	 also	 experiencing	 greater	 emo-
tional	distress	because	of	their	AF.	TTR	<50%	patients	reported	be-
lieving	more	strongly	in	the	potential	for	harm	from	pharmaceutical	
products	accompanied	by	greater	concerns	regarding	VKAs	specifi-
cally,	whilst	perceiving	it	to	be	less	necessary.	According	to	both	the	
benefits	and	burdens	subscales,	TTR	<50%	patients	had	lower	treat-
ment	satisfaction.
For	VTE	patients,	 illness	beliefs	were	broadly	similar	to	AF	pa-
tients	with	some	key	exceptions:	TTR	<50%	patients	have	lower	ill-
ness	coherence	and	do	not	experience	different	levels	of	emotional	
distress.	While	TTR	<50%	VTE	patients	have	greater	concerns	about	
VKAs,	 both	 groups	 have	 similar	 beliefs	 regarding	 the	 necessity	 of	
anticoagulation	treatment.	There	were	no	differences	in	treatment	
satisfaction.
3.2 | Patterns of beliefs
Cluster	analysis	revealed	four	distinct	belief	sets	(Table	4).	Cluster	1	
were	accepting	of	both	their	therapy	and	their	illness,	cluster	2	was	
cautious	of	 therapy	but	accepting	of	 their	 illness,	 cluster	3	was	ac-
cepting	of	therapy	but	fearful	about	their	illness,	while	cluster	4	was	
cautious	of	therapy	and	fearful	of	their	disease.	Clinical	demograph-
ics	according	to	cluster	are	shown	in	Table	5.	Cluster	1	was	the	most	
populous	where	patients	were	likely	to	be	well	controlled	with	VKAs.	
Over	65%	of	patients	in	cluster	4	were	poorly	controlled	on	VKAs	and	
over	50%	of	patients	in	this	cluster	were	female	compared	to	approxi-
mately	35%	in	all	other	clusters.	Post	hoc	analysis	of	subscale	scores	
showed	 significant	 differences	 between	 clusters	 in	 every	 subscale,	
validating	the	cluster	analysis,	see	Supplementary	Table	S2.
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TABLE  2 Clinical	and	Demographic	Information	of	Recruited	Patients
AF patients VTE patients Other diagnosesa,b
TTR >75% 
(n = 187)
TTR <50% 
(n = 164) Sig.
TTR >75% 
(n = 89)
TTR <50% 
(n = 43) Sig.
TTR >75% 
(n = 35)
TTR <50% 
(n = 7)
TTR	(median,	IQR) 90	(81-	100) 39	(33-	45) — 95	(87-	100) 38	(32-	44) — 97	(89-	100) 35	(34-	36)
KCHc	(n,	%) 86	(46) 66	(40) 0.278 41	(46) 23	(53) 0.424 19	(54) 3	(43)
Male	(n,	%) 112	(60) 105	(64) 0.427 53	(60) 24	(56) 0.693 26	(74) 4	(47)
Caucasian	(n,	%) 175	(94) 143	(90) 0.215 77	(87) 31	(72) 0.044 32	(91) 7	(100)
Age	(median,	IQR) 78	(71-	84) 74	(66-	81) <0.001 69	(61-	77) 54	(46-	66) <0.001 72	(63-	79) 53	(50-	68)
Duration	of	
Warfarin	
Therapy	in	weeks	
(median,	IQR)
221	(129-	352) 116	(41-	275) <0.001 269	(127-	595) 139	(78-	260) <0.001 299	(154-	610) 194	(133-	198)
CHADS2  
(mean,	SD)d
2.22	(1.23) 2.15	(1.26) 0.601 N/A NA
CHA2DS2VASc	
(mean,	SD)e
3.61	(1.44) 3.37	(1.45) 0.130 N/A NA
HAS-	BLED	(mean,	
SD)f
1.47	(0.67) 2.44	(0.85) <0.001 0.98	(0.75) 1.74	(0.66) <0.001 1.67	(1.04) 2.14	(1.35)
Adjusted	
HAS-	BLED	
(mean,	SD)
1.47	(0.67) 1.44	(0.85) 0.682 0.98	(0.75) 0.74	(0.66) <0.087 1.67	(1.04) 1.14	(1.35)
SAMe-	TT2R2
g 
(mean,	SD)
1.24	(0.89) 1.48	(1.11) 0.035 1.17	(1.11) 2.26	(1.16) <0.001 1.11	(0.94) 2.86	(1.07)
CCI	10	year	
mortality  
(mean,	SD)h
0.27	(0.26) 0.21	(0.29) 0.057 0.47	(0.33) 0.60	(0.39) 0.066 0.43	(0.29) 0.28	(0.28)
Congestive	Heart	
Failure	(n,	%)
51	(30) 51	(31) 0.828 8	(9) 1	(2) 0.143 6	(22) 6	(86)
Hypertension	 
(n,	%)
106	(62) 99	(60) 0.709 40	(47) 14	(33) 0.130 13	(48) 2	(29)
Stroke	(n,	%) 38	(22) 36	(22) 0.930 1	(1) 2	(5) 0.215 7	(26) 5	(71)
Vascular	Disease	
(n,	%)
13	(8) 10	(6) 0.576 4	(5) 3	(7) 0.583 1	(4) 0	(0)
Type	II	Diabetes	
Mellitus	(n,	%)
28	(16) 41	(25) 0.054 14	(16) 6	(14) 0.731 6	(22) 1	(14)
Bleeding	History	
(n,	%)
21	(12) 20	(12) 0.965 7	(8) 3	(7) 0.816 5	(19) 1	(14)
Myocardial	
Infarction	(n,	%)
28	(16) 16	(10) 0.073 3	(3) 3	(7) 0.375 7	(26) 3	(43)
Ischaemic Heart 
Disease	(n,	%)
46	(27) 46	(28) 0.840 6	(7) 3	(7) 1.000 9	(33) 3	(43)
aAortic	valve	replacement,	mitral	valve	replacement,	left	ventricular	thrombus.
bDue	to	small	number	of	participants	in	this	group,	statistical	tests	not	performed.
cKing’s	College	Hospital	Clinic	Site.
dCHADS2:	congestive	heart	failure,	hypertension,	diabetes	and	age	>75	years	are	assigned	1	point,	prior	stroke/TIA	assigned	2	points.
eCHA2DS2VASc:	congestive	heart	failure,	hypertension,	diabetes,	female	gender,	vascular	disease	and	an	age	of	65-	74	years	assigned	1	point,	prior	
stroke/TIA	and	age	>75	years	assigned	2	points.
fHAS-	BLED:	uncontrolled	hypertension,	severe	renal	 impairment,	 liver	disease,	stroke,	bleeding	history,	TTR	<60%,	age	>65	years,	drug	 increasing	
bleeding	risk,	alcohol	consumption	>8	drinks/wk.
gSAMe-	TT2R2:	female	gender,	age	<60	years,	2	of:	hypertension,	diabetes,	peripheral	artery	disease,	congestive	heart	failure,	stroke,	respiratory	dis-
ease,	liver	disease,	renal	disease,	myocardial	infarction,	interacting	treatment	assigned	1	point,	tobacco	use	in	previous	2	years	and	non-	Caucasian	race	
assigned	2	points.
hCharlson	Co-	Morbidity	Index	Predicting	likelihood	of	10	year	mortality.
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3.3 | Factors influencing TTR
Variables	linked	with	low	TTR	according	to	univariate	logistic	regres-
sion with P ≤ .1	that	were	subsequently	entered	into	a	multivariate	
model	 determining	 TTR	 <50%	were:	 ethnicity,	 diagnosis,	 drug	 in-
creasing	bleed	risk,	thrombotic	history,	belief	cluster,	and	concurrent	
ACE-	inhibitor	prescription.	The	reference	category	for	nominal	vari-
ables	were:	Caucasian	ethnicity,	diagnosis	of	AF,	not	being	prescribed	
TABLE  3  Independent	T-	tests	for	Subscales	Measured
Questionnaire Subscale
AF patients VTE patients
TTR >75% 
(n = 187) 
Mean (SD)
TTR <50% 
(n = 164) 
Mean (SD) Sig.
TTR >75% 
(n = 89) 
Mean (SD)
TTR <50% 
(n = 43) 
Mean (SD) Sig.
IPQ-	R Timeline	Acute	
Chronic
24.3	(3.8) 23.1	(4.1) 0.008 25.2	(4.3) 23.3	(5.0) 0.015
Timeline	Cyclical 8.9	(3.1) 10.4	(3.2) 0.001 8.0	(3.3) 10.3	(3.7) 0.002
Consequences 16.2	(3.9) 17.6	(4.4) 0.003 16.8	(4.1) 18.4	(4.5) 0.037
Personal	Control 18.8	(4.4) 19.7	(4.0) 0.089 18.4	(4.8) 19.8	(4.0) 0.141
Treatment	Control 16.4	(2.3) 16.9	(2.6) 0.074 17.1	(2.4) 17.1	(3.0) 0.898
Illness	Coherence 18.5	(3.9) 18.3	(3.9) 0.446 18.9	(4.0) 17.2	(4.4) 0.027
Emotional	Response 14.2	(4.4) 15.3	(4.7) 0.006 14.5	(5.4) 15.8	(5.1) 0.230
Psychological	Cause 13.4	(4.1) 13.4	(4.0) 0.533 11.4	(3.9) 13.0	(4.5) 0.067
Risk	Factor	Cause 17.0	(3.9) 17.8	(4.2) 0.067 15.3	(3.8) 16.5	(5.1) 0.255
Immune	Cause 6.4	(1.9) 6.8	(1.7) 0.017 6.0	(2.1) 6.9	(2.5) 0.041
Accidental	Cause 4.5	(1.5) 4.6	(1.5) 0.142 5.2	(1.7) 5.6	(1.8) 0.184
BMQ General Harm 19.9	(6.5) 23.5	(8.0) 0.044 8.9	(2.4) 9.7	(2.9) 0.141
General Overuse 11.4	(2.7) 10.1	(2.7) 0.075 11.2	(2.7) 11.8	(3.3) 0.281
Specific	Concern 12.0	(3.5) 13.9	(3.7) 0.001 13.0	(3.6) 14.6	(4.4) 0.032
Specific	Necessity 17.3	(3.7) 16.5	(3.2) 0.017 18.5	(3.6) 17.8	(3.8) 0.196
ACTS Burdens 19.9	(6.5) 23.5	(8.0) 0.001 23.5	(8.3) 26.3	(9.3) 0.093
Benefits 11.4	(2.7) 10.1	(2.7) 0.001 11.7	(2.9) 11.6	(2.4) 0.721
TABLE  4 Cluster	Characteristics
Cluster Description
Accepting of therapy and 
illness
Cautious of therapy not 
illness
Accepting of therapy but 
fearful of illness
Cautious of therapy and 
fearful of illness
Timeline	Acute	
Chronic
Very	Chronic Chronic Very	Chronic Chronic
Timeline	Cyclical Stable Stable Stable Unsure
Consequences Mild Mild Mild Moderate
Personal	Control High High High High
Treatment	Control High Moderate Moderate Moderate
Illness	Coherence High Moderate High Moderate
Emotion Low Low Moderate Moderate
General Harm Low Low Low Low
General Overuse Low Moderate Moderate Moderate
Specific	Concern Low Moderate Moderate High
Specific	Necessity High Moderate High High
Burdens Very	Low Very	Low Low Moderate
Benefits High Moderate High Moderate
Key:	Highly	Positive	Health	Belief:	 .
Positive	Health	Belief:	 .
Borderline	Health	Belief:	 .
Negative	Health	Belief:	 .
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an	ACE-	inhibitor	or	drug	increasing	bleeding	risk,	no	thrombotic	his-
tory,	and	belief	cluster	1.	The	resulting	model	found	that	only	diag-
nosis	 and	belief	 cluster	were	 associated	with	TTR	<50%	 (Table	6).	
VTE	patients	were	more	 than	half	as	 likely	 to	have	poor	 INR	con-
trol	 (OR	=	0.49;	95%	CI	0.29,	0.77)	while	 there	was	 increasing	 risk	
moving	from	cluster	1	to	4	where	cluster	4	patients	were	over	four	
times	more	 likely	 to	be	poorly	controlled	 (OR	=	4.75;	95%	CI	2.75,	
8.77).	 This	model	 describes	 65%	of	 the	 variance	 in	 TTR	 category.	
Age,	gender,	income,	life	expectancey,	and	disease	severity	were	not	
associated	with	TTR	according	to	regression	analysis,	and	thus	the	
model	was	not	adjusted	for	variables	such	as	age	or	gender	(see	sup-
plementary	information).
3.4 | AF versus VTE
Comparing	AF	and	VTE	patients	with	TTR	>75%	(Table	7)	revealed	
VTE	patients	have	greater	concerns	about	therapy,	necessity	beliefs,	
and	burdens	compared	to	AF	patients.	These	VTE	patients	also	had	
greater	conviction	 in	 their	 illness	being	caused	by	accident	or	bad	
luck.	AF	patients	with	TTR	>75%	were	more	likely	to	attribute	their	
illness	 to	 psychological	 causes	 such	 as	 stress,	 family	 problems,	 or	
overwork.	AF	patients	were	also	more	likely	to	believe	that	their	ill-
ness	was	caused	by	risk	factors	such	as	genetics,	unhealthy	eating,	
and	poor	medical	care.
Comparing	AF	and	VTE	patients	with	TTR	<50%	demonstrated	
that	VTE	patients	had	greater	specific	necessity	beliefs	relating	to	
VKAs	 and	 were	 more	 likely	 to	 recognize	 the	 benefits	 of	 therapy	
than	AF	patients.	Although	compared	to	AF	patients,	VTE	patients	
reported	greater	burdens	of	VKA	therapy,	this	was	not	statistically	
significant.	 Like	 those	with	 TTR	>75%,	VTE	 patients	 in	 this	 group	
attributed	their	illness	to	accident	or	bad	luck	more	frequently	than	
AF	patients.	There	were	no	significant	differences	in	NCDs	between	
AF	and	VTE	in	either	optimal	or	suboptimal	groups	(Supplementary	
Tables	3	and	4).
4  | DISCUSSION
This	study	has	demonstrated	how	illness	beliefs,	medication	beliefs,	
and	anticoagulation-	specific	QoL	and	 treatment	 satisfaction	differ	
between	those	with	optimal	(TTR	>75%)	and	suboptimal	(TTR	<50%)	
INR	control.	To	our	knowledge,	this	is	the	first	study	designed	to	ex-
amine	the	differing	beliefs	between	these	groups	and	to	determine	
belief	patterns	associated	with	TTR.	The	differences	in	beliefs	were	
largely	similar	 for	both	 the	AF	and	VTE	patients,	albeit	with	some	
exceptions.	 In	examining	the	differences	between	the	two	groups,	
there	 are	 two	key	aspects	 to	 this	VKA	experience:	understanding	
and	knowledge	of	illness	and	subjective	experiences	of	their	illness	
and treatment.
Cluster 1 
(n = 186)
Cluster 2 
(n = 92)
Cluster 3 
(n = 120)
Cluster 4 
(n = 76)
Age	(median,	IQR) 73	(66-	81) 77	(69-	84) 72	(62-	78) 70	(61-	77)
TTR	>75%	(n,	%) 132	(71.0) 47	(51.1) 64	(53.3) 28	(36.8)
Male	(n,	%) 121	(65.1) 60	(65.2) 78	(65.0) 37	(48.7)
Caucasian	(n,	%) 180	(96.8) 79	(87.8) 103	(86.6) 61	(81.3)
AF	(n,	%) 127	(68.3) 68	(73.9) 75	(62.5) 47	(61.8)
VTE	(n,	%) 43	(23.1) 21	(22.8) 34	(28.3) 22	(29.0)
Other	(n,	%) 16	(8.6) 3	(3.3) 11	(9.2) 7	(9.2)
CHADS2	(mean,	SD)
a 2.1	(1.2) 2.3	(1.4) 2.3	(1.4) 2.0	(1.0)
CHA2DS2VASc	(mean,	
SD)a
3.4	(1.3) 3.6	(1.6) 3.4	(1.6) 3.4	(1.2)
HAS-	BLED	(mean,	SD) 1.7	(1.0) 1.9	(0.9) 1.8	(0.9) 1.8	(0.9)
CCI	10	year	mortality	
(mean,	SD)
0.4	(0.3) 0.3	(0.3) 0.3	(0.3) 0.3	(0.3)
SAME-	TTR	(mean,	SD) 1.1	(0.9) 1.4	(1.1) 1.4	(1.1) 1.9	(1.2)
aAF	patients	only.
TABLE  5 Clinical	and	Demographic	
Characteristics	of	Clusters
TABLE  6 Unadjusted	Binary	Logistic	Regression	Model	
Predicting	TTR	<50%
Odds ratio (OR)
95% C.I. for OR
Lower Upper
AF	(Ref) 1.00 — —
 VTE 0.49 0.29 0.77
 Other 0.22 0.07 0.46
Cluster	1	(Ref) 1.00 — —
 Cluster	2 2.25 1.35 3.77
 Cluster	3 2.32 1.42 3.74
 Cluster	4 4.75 2.75 8.77
Diagnosis	of	AF	and	Cluster	1	were	baseline	comparators.
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4.1 | Understanding and knowledge of illness
Despite	all	patients	being	prescribed	VKAs	lifelong,	timeline	beliefs	
were	 markedly	 different	 between	 groups.	 Those	 with	 TTR	 >75%	
with	 either	 condition	 believed	 more	 strongly	 in	 the	 chronic	 and	
noncyclical	nature	of	their	illness.	This	accompanied	by	lower	illness	
coherence	among	TTR	<50%	VTE	patients,	highlights	a	knowledge	
deficit	among	patients	with	TTR	<50%	about	the	course	and	nature	
of	their	illness.
Among	AF	patients,	those	with	TTR	<50%	believed	less	in	VKA	
necessity,	indicating	these	patients	may	be	less	aware	of	the	risk	
of	stroke	associated	with	AF	and	the	role	anticoagulation	plays	in	
preventing	 it.	Conversely,	VTE	patients	had	similar	necessity	be-
liefs	across	the	board.	This	is	likely	to	be	related	to	VKA	therapy	
being	the	active	treatment	used	for	acute	VTE	and	therefore	they	
placed	a	higher	value	on	VKA	treatment	for	secondary	prevention.	
Research	elsewhere	has	demonstrated	that	a	strong	sense	of	ne-
cessity,	 is	 linked	to	better	adherence	while	strong	concerns	have	
the	opposite	effect.37	In	practice,	clinicians	should	elicit	these	be-
liefs	at	the	outset	to	ensure	appropriate	understanding.	Although	
interventions	 in	 anticoagulation	 that	 have	 targeted	 education	
alone	have	had	limited	success,38,39	there	is	scope	to	improve	TTR	
by	addressing	inaccurate	beliefs	if	combined	with	other	behavior	
change	 techniques.	 Interventions	 utilising	 nonmedical	 personnel	
such	as	pharmacists	and	nurses	have	proved	to	be	successful.40
4.2 | Subjective experiences of illness and treatment
AF	 patients	 with	 TTR	 <50%	 reported	 fewer	 benefits	 of	 antico-
agulation	 and	 greater	 emotional	 distress,	 specific	 concerns	 and	
burdens	of	therapy,	while	TTR	<50%	VTE	patients	scored	higher	
in	specific	concerns	and	trended	towards	greater	burdens.	This	is	
indicative	 of	 negative	 experiences	 regarding	 emotional	 wellbe-
ing	and	treatment	satisfaction.	This	is	consistent	with	Lane	et	al’s	
work	 which	 found	 that	 high	 baseline	 specific	 concern	was	 con-
sistent	with	worse	QoL.41	 It	 is	 likely	 that	 the	experience	of	out-	
of-	range	 INR	 results,	 dose	 changes,	 and	 more	 frequent	 testing	
has	 perpetuated	 negative	 perceptions.	 In	 conjunction	 with	 this,	
interactions	from	the	clinic	including	phone	calls	enquiring	about	
blood	loss	and	bruising	may	contribute	to	the	patient’s	raised	risk	
perception	as	demonstrated	by	TTR	<50%	patients’	strong	sense	
that	their	illness	has	severe	consequences.42
TTR	>75%	patients	were	prescribed	VKAs	on	average	nearly	
2	years	longer	than	TTR	<50%	patients.	This	may	explain	some	of	
the	differences	as	optimal-	TTR	patients	had	 longer	 to	establish	
beliefs	and	behaviors	around	 their	VKAs.	However,	duration	of	
VKA	 therapy	 was	 not	 associated	 with	 TTR	 category	 in	 regres-
sion	 analyses.	 Furthermore,	 it	 is	 to	 be	 expected	 that	 patients	
with	TTR	<50%	have	a	shorter	duration	of	therapy	as	guidelines	
dictate	that	these	patients	should	be	considered	for	switching	to	
DOAC.2,8
TABLE  7  Independent	T-	Tests	Comparing	AF	and	VTE	Patients	Within	TTR	Group
Questionnaire Subscale
TTR >75% TTR <50%
AF 
(n = 187) 
Mean (SD)
VTE 
(n = 89) 
Mean (SD) Sig.
AF 
(n = 164) 
Mean (SD)
VTE 
(n = 43) 
Mean (SD) Sig.
IPQ-	R Timeline	Acute	
Chronic
24.3	(3.8) 25.2	(4.3) 0.092 23.1	(4.1) 23.3	(5.0) 0.889
Timeline	Cyclical 8.9	(3.1) 8.0	(3.3) 0.200 10.4	(3.2) 10.3	(3.7) 0.724
Consequences 16.2	(3.9) 16.8	(4.1) 0.283 17.6	(4.4) 18.4	(4.5) 0.374
Personal	Control 18.8	(4.4) 18.4	(4.8) 0.595 19.7	(4.0) 19.8	(4.0) 0.927
Treatment	Control 16.4	(2.3) 17.1	(2.4) 0.075 16.9	(2.6) 17.1	(3.0) 0.915
Illness	Coherence 18.5	(3.9) 18.9	(4.0) 0.529 18.3	(3.9) 17.2	(4.4) 0.119
Emotional	Response 14.2	(4.4) 14.5	(5.4) 0.337 15.3	(4.7) 15.8	(5.1) 0.586
Psychological	Cause 13.4	(4.1) 11.4	(3.9) 0.001 13.4	(4.0) 13.0	(4.5) 0.245
Risk	Factor	Cause 17.0	(3.9) 15.3	(3.8) 0.001 17.8	(4.2) 16.5	(5.1) 0.051
Immune	Cause 6.4	(1.9) 6.0	(2.1) 0.135 6.8	(1.7) 6.9	(2.5) 0.999
Accidental	Cause 4.5	(1.5) 5.2	(1.7) 0.004 4.6	(1.5) 5.6	(1.8) 0.003
BMQ General Harm 19.9	(6.5) 8.9	(2.4) 0.097 23.5	(8.0) 9.7	(2.9) 0.074
General Overuse 11.4	(2.7) 11.2	(2.7) 0.478 10.1	(2.7) 11.8	(3.3) 0.500
Specific	Concern 12.0	(3.5) 13.0	(3.6) 0.020 13.9	(3.7) 14.6	(4.4) 0.340
Specific	Necessity 17.3	(3.7) 18.5	(3.6) 0.012 16.5	(3.2) 17.8	(3.8) 0.042
ACTS Burdens 19.9	(6.5) 23.5	(8.3) 0.001 23.5	(8.0) 26.3	(9.3) 0.069
Benefits 11.4	(2.7) 11.7	(2.9) 0.704 10.1	(2.7) 11.6	(2.4) 0.004
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4.3 | Belief patterns associated with TTR
Cluster	 analysis	 revealed	 four	 distinct	 patterns	 of	 beliefs	 among	
patients	 ranging	 from	cluster	1,	who	were	accepting	of	both	 their	
therapy	and	 illness,	 to	 those	who	were	 fearful	of	both,	 i.e,	 cluster	
4.	Regression	analysis	 found	patients	at	 the	highest	 risk	of	having	
poor	INR	control	were	those	with	AF	and	beliefs	akin	to	cluster	4.	
Although	cluster	4	was	made	up	of	disproportionately	more	women,	
gender	was	unrelated	 to	TTR	 in	 the	 regression	analysis	and	 is	not	
consistently related to adherence or TTR in the literature.22
VTE	patients	were	less	likely	to	have	low	TTR.	This	may	be	due	
to	previous	experience	of	thrombosis	where	VKAs	were	the	active	
treatment.	 Referring	 to	 the	 COM-	B	 model,	 motivation	 to	 adhere	
would	 be	 enhanced,	 while	 enhancing	 necessity	 perceptions.	 The	
TREAT	 study	 found	 that	 baseline	 specific	 necessity	 beliefs	 were	
predictive	of	 INR	 control	 at	 1	year.	 Furthermore,	 they	 established	
links	between	baseline	negative	beliefs	about	medication	and	TTR.43 
This	finding	is	supported	by	our	analysis	where	TTR	>75%	patients	
have	higher	necessity	beliefs.	AF	patients	with	a	history	of	stroke	did	
not	report	higher	emotional	distress	or	specific	necessity	than	those	
without	 stroke,	 although	 the	 number	 of	 stroke	 patients	was	 rela-
tively	small.	Stroke	was	unrelated	to	TTR	in	the	regression	analysis.
The	 regression	 analysis	 has	been	 reported	unadjusted	 for	 age,	
gender,	 or	 any	 other	 clinical-	demographic	 variable.	 The	 develop-
ment	of	this	model	was	exploratory	and	all	variables	underwent	uni-
variate	logistic	regression	to	determine	any	association	with	TTR,	as	
no	clinical-	demographic	variable	influenced	TTR,	none	was	adjusted	
for	in	the	final	multivariate	model.	Within	the	literature,	there	is	no	
strong	 evidence	 that	 any	 clinical	 demographic	 is	 associated	 with	
adherence	to	anticoagulation	or	TTR	that	would	provide	a	basis	by	
which	to	adjust	for	them,22,44 nor is there a theoretical basis to do so.
4.4 | Beliefs of AF and VTE patients
TTR	>75%	VTE	patients	had	a	greater	recognition	of	the	necessity	
for	VKA	 therapy	 compared	 to	 those	with	AF,	 similar	 to	 findings	
in	Dutch	patients.45	Unexpectedly,	our	VTE	patients	had	greater	
concerns	and	reported	more	burdens	related	to	VKAs.	The	NCDs	
between	AF	 and	VTE	patients	were	 similar	 in	 both	 groups.	 This	
is	 in	 contrast	 to	 previous	 research,	 which	 has	 found	 that	 VTE	
patients	 had	 higher	 differentials	 compared	 to	 AF	 patients.45	 A	
possible	 explanation	 for	 this	 is	 our	 VTE	 patients	 were	 on	 aver-
age	10	years	younger	and	younger	age	has	been	associated	with	
worse adherence elsewhere.46,47	Furthermore,	as	the	AF	popula-
tion	was	more	comorbid,	VTE	patients	were	likely	to	recognize	the	
burden	of	their	illness	more	than	AF	patients	where	AF	is	one	of	
many	illnesses.	Beyond	this,	although	not	statistically	significant,	
VTE	 patients	 exhibited	 stronger	 consequence	 beliefs	 regarding	
their	 illness.	As	all	VTE	patients	had	experienced	a	symptomatic	
event	previously,	this	heightened	risk	perception	compared	to	AF	
patients	is	intuitive.	Kaptein	et	al	previously	reported	that	among	
those	at	high	risk	of	thrombosis,	those	who	had	previous	experi-
ence	of	a	thrombus	had	significantly	higher	risk	perception.48 This 
could	explain	 the	 raised	necessity	 and	consequence	perceptions	
in	VTE.
4.5 | Validity of study tools
The	high	internal	consistency	through	Cronbach’s	alpha	validates	the	
use	of	the	IPQ-	R,	BMQ,	and	ACTS	for	use	in	AF	and	VTE	patients	
prescribed	VKAs.35	The	exceptions	were	the	accidental	cause	of	the	
treatment	control	subscales.	The	latter	is	mitigated	through	the	anal-
ogous	subscales	from	the	BMQ	and	ACTS	questionnaires	and	was	
not	improved	by	removing	any	one	question	from	the	subscale.	The	
alpha	score	 for	accidental	cause	 is	similar	 to	 that	of	 the	validation	
study	for	IPQ-	R	and	is	low	due	to	there	being	only	two	questions	in	
the subscale.31
4.6 | Implications for practice
This	research	has	demonstrated	that	beliefs	vary	significantly	with	
TTR.	Furthermore,	the	regression	analysis	has	shown	that	beliefs	are	
associated	with	TTR.	Although	potentially	useful	for	screening	pur-
poses,	 clinical	 demographic	 variables	 such	 as	 age,	 gender,	 disease	
severity,	duration	of	warfarin	treatment,	comorbidities,	and	income	
were	 not	 associated	with	 TTR.	 Even	 if	 they	were,	 these	 variables	
are	nonmodifiable.	Crucially,	beliefs	can	be	modified.	Beliefs	that	are	
prevalent	among	those	with	low	TTR	could	potentially	be	targeted	to	
initiate	behavior	change	with	the	goal	of	improving	TTR	and	adher-
ence.	In	the	age	of	DOACs,	where	the	consensus	is	that	patients	with	
poor	TTR	should	be	considered	 for	DOAC	 treatment,	 these	belief	
patterns	still	need	to	be	addressed	and	can	act	as	a	valuable	tool	in	
effective	patient	management.
4.7 | Limitations
While	low	TTR	is	associated	with	poor	adherence	to	VKAs,	it	is	not	
the	only	cause.	Other	factors	include	dietary	intake,	other	medica-
tion,	genetic	polymorphism,	or	 inappropriate	VKA	dosing.	This	 is	a	
noninterventional	 study	and	all	TTR	<50%	patients	were	asked	 to	
complete	their	questionnaire	prior	to	consultation	to	prevent	bias;	
however,	 some	 incomplete	 questionnaires	were	 submitted.	 In	 this	
case	patients	were	asked	to	be	complete	missing	answers	after	the	
consultation,	potentially	affecting	 the	 results	 in	a	small	number	of	
patients.	This	study	also	does	not	provide	insight	into	beliefs	about	
VKAs	 in	the	context	of	the	patient’s	other	medication.	Due	to	the	
cross-	sectional	nature	of	this	study,	the	beliefs	of	patients	with	TTR	
between	51%	and	74%	are	unknown.
5  | CONCLUSIONS
This	study	has	demonstrated	that	illness	beliefs,	medication	beliefs,	
and	 QoL	 in	 patients	 prescribed	 chronic	 VKA	 therapy	 are	 signifi-
cantly	associated	with	the	behavior	of	anticoagulated	patients	and	
are	 associated	with	 INR	 control.	 The	multiple	 disparities	 between	
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those	with	TTR	>75%	and	TTR	<50%	groups	can	be	targeted	through	
theory-	driven	interventions	to	attempt	improving	TTR	and	support	
medication adherence.
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